Duloxetine-mirtazapine combination in depressive illness: The case for Limerick 'rocket fuel'

Irish Journal of Psychological Medicine

Volumn 23, Issue 3, 2006, Pages

  Meagher, David ^a   Hannan, Noel ^a   Leonard, Maeve ^a  

^a UNIVERSITY HOSPITAL LIMERICK   (Ireland)

Author keywords

Adverse effects; Antidepressant; Combination; Depression; Duloxetine; Hypomanic switch; Mirtazapine; Treatment

Indexed keywords

DULOXETINE; MIRTAZAPINE; RISPERIDONE; VENLAFAXINE;

ADULT; ALLERGIC RASH; ANAMNESIS; ARTICLE; CASE REPORT; DEPRESSION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MIXTURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOMANIA; INSOMNIA; MALE; MENTAL HEALTH; NAUSEA; PATIENT COMPLIANCE;

EID: 33750467368     PISSN: 07909667     EISSN: 07909667     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Fawcett J, Barkin RL. Efficacy issues with antidepressants. J Clin Psychiatry 1997: 58(6): 32-9.
2. O'Reardon JP, Amsterdam JD. Treatment-resistant depression:progress and limitations. Psychiatr Ann 1998: 28; 633-40.
3. Fava D, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin N Am 1996; 19: 179-200.
4. Taylor D, Paton C, Kerwin R. The South London and Maudsley NHS Trust 2005-2006 Prescribing Guidelines : 8th Edition. Taylor and Francis, Oxon, UK, 2005.
5. National Institute of Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guideline 23, December 2004.
6. Stahl SM. Essential Psychopharmacology : Neuroscientific basis and practical applications (2nd edition). Cambridge University Press, 2000.
7. Aydemir O, Taskin EO, Deveci A. Mirtazapine augmentation in treatment-resistant major depressive disorder: an open-label, six week trial. European Neuropsychopharmacology 2005;15(3): 401-2.
8. Blier P, Tremblay PM, Ward HE, Hebert C, Bergeron R. Antidepressant drug combination from treatment initiation to improve therapeutic response in major depression. European Neuropsychopharmacology 2005; 15(3): 449-450.
9. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with Mirtazapine. Biol Psychiatry 2002; 51:183-188.
10. Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999; 60: 45-49.
11. Hannan N, Akinpeloye H, Hamzah Z, Meagher D. Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness. J Psychopharmacology (in press).
12. Klotz U. Tramadol - the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Arzneimittelforschung 2003; 53: 681-7.
13. Hopwood SE, Owesson CA, Callado LF, et al. Effects of chronic tramadol on pre-and post-synaptic measures of monoamine function. J Psychopharmacol 2001; 15: 147-153.
14. Houlihan DJ. Serotonin syndrome resulting from co-administration of tramadol, venlafaxine, and mirtazapine. Ann Pharmacother 2004; 38: 411-3.
15. Perahia D, Pritchett YL, Walker D, et al. Comparing duloxetine and venlafaxine in the treatment of major depressive disorder using a global benefit-risk approach. Presented at the New Clinical Drug Evaluation Unit (NCDEU), June 6-9, 2005, Florida.
16. de Montigny C, Silverstone PH, Debonnel G, Blier P, Bakish D. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol 1999: 19; 401-6.
17. Mitchell PB, Schweitzer I, Burrows G, Johnson G, Polonowita A. Efficacy of venlafaxine and predictors of response in an open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol 2000: 20; 483-7.
18. Wohlreich MM, Mallinckrodt CH, Watkin JG, Wilson MG, Greist JH, Delgado PL, Fava M. Immediate switching of antidepressant therapy:results from a clinical trial of duloxetine. Ann Clin Psychiatry 2005: 17; 259-68.
19. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871-880.
20. Bhanji NH, Margolese HC, Saint-Laurent M, Chouinard G. Dysphoric mania induced by high-dose mirtazapine: a case for 'norepinephrine syndrome'. Int Clin Psychopharmacol 2002; 17: 319-322.
21. Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord 2003; 5: 407-420.
22. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced mannis conversion. Arch Pediatr Adolesc Med 2004: 158; 773-80.
23. Hadjipavlou G, Mok H, Yatham LN. Bipolar II disorder: an overview of recent developments. Can J Psychiatry 2004: 49; 802-12.
24. Simpson SG, McMahon FJ, McInnis MG, MacKinnon DF, et al. Diagnostic reliability of bipolar II disorder. Arch Gen Psychiatry 2002: 59; 736-40.
25. Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the mood disorder questionnaire Am J Psychiatry 2000: 157; 1873-5.
26. Shelton RC. The dual-action hypothesis: does pharmacology matter? J Clin Psychiatry 2004 (17): 65; 5-10.